BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Candia J, Bayarsaikhan E, Tandon M, Budhu A, Forgues M, Tovuu LO, Tudev U, Lack J, Chao A, Chinburen J, Wang XW. The genomic landscape of Mongolian hepatocellular carcinoma. Nat Commun 2020;11:4383. [PMID: 32873799 DOI: 10.1038/s41467-020-18186-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Wang Z, Jia F, Xu Q, Shu Z, Deng J, Li A, Yu M, Yu Z. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioactive Materials 2022;17:147-61. [DOI: 10.1016/j.bioactmat.2022.01.003] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Guo C, Tang Y, Yang Z, Li G, Zhang Y. Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates. Front Immunol 2022;13:958161. [DOI: 10.3389/fimmu.2022.958161] [Reference Citation Analysis]
3 Liu H, Zhu J, Guo L, Zhang H, Liu S, Kou X, Zhang Z. Identification of a Two-lncRNA Signature with Prognostic and Diagnostic Value for Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/2687455] [Reference Citation Analysis]
4 Das S, Thakur S, Korenjak M, Sidorenko VS, Chung FF, Zavadil J. Aristolochic acid-associated cancers: a public health risk in need of global action. Nat Rev Cancer 2022. [PMID: 35854147 DOI: 10.1038/s41568-022-00494-x] [Reference Citation Analysis]
5 Liu J, Jia J, Wang S, Zhang J, Xian S, Zheng Z, Deng L, Feng Y, Zhang Y, Zhang J. Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer. Molecules 2022;27:4108. [DOI: 10.3390/molecules27134108] [Reference Citation Analysis]
6 Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med 2022;14:eabo4474. [PMID: 35731891 DOI: 10.1126/scitranslmed.abo4474] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol 2022;19:367-82. [PMID: 35273358 DOI: 10.1038/s41575-022-00587-w] [Reference Citation Analysis]
8 Shagdarsuren O, Khuyag S, Mukhtar Y, Mandakh U, Tsogzolbaatar E, Shaarii S, Batsuren N, Namdag B, Radnaa O, Dambadarjaa D. Post-vaccination Immunity Against Hepatitis B Among Mongolian Adolescents and Youths. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon-121383] [Reference Citation Analysis]
9 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
10 Ma L, Wang XW. Dissecting liver tumor heterogeneity to improve health equity. Trends Cancer 2022:S2405-8033(21)00249-1. [PMID: 35012904 DOI: 10.1016/j.trecan.2021.12.001] [Reference Citation Analysis]
11 Li S, Liu T, Li K, Bai X, Xi K, Chai X, Mi L, Li J. Spectrins and human diseases. Transl Res 2021:S1931-5244(21)00306-6. [PMID: 34979321 DOI: 10.1016/j.trsl.2021.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bai H, Cheng Y, Che J. Pharmacokinetics and Disposition of Heparin-Binding Growth Factor Midkine Antisense Oligonucleotide Nanoliposomes in Experimental Animal Species and Prediction of Human Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model. Front Pharmacol 2021;12:769538. [PMID: 34803711 DOI: 10.3389/fphar.2021.769538] [Reference Citation Analysis]
13 Schäffer AA, Dominguez DA, Chapman LM, Gertz EM, Budhu A, Forgues M, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Wu X, Bayarsaikhan E, Harris CC, Ruchirawat M, Ruppin E, Wang XW. Integration of adeno-associated virus (AAV) into the genomes of most Thai and Mongolian liver cancer patients does not induce oncogenesis. BMC Genomics 2021;22:814. [PMID: 34763675 DOI: 10.1186/s12864-021-08098-9] [Reference Citation Analysis]
14 Scheiter A, Evert K, Reibenspies L, Cigliano A, Annweiler K, Müller K, Pöhmerer LM, Xu H, Cui G, Itzel T, Materna-Reichelt S, Coluccio A, Honarnejad K, Teufel A, Brochhausen C, Dombrowski F, Chen X, Evert M, Calvisi DF, Utpatel K. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues. Mol Oncol 2021. [PMID: 34748271 DOI: 10.1002/1878-0261.13135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Chen Y, Wang X, Deng X, Zhang Y, Liao R, Li Y, Yang H, Chen K. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Front Immunol 2021;12:676922. [PMID: 34335575 DOI: 10.3389/fimmu.2021.676922] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
16 Wang H, Ding Y, Chen Y, Jiang J, Chen Y, Lu J, Kong M, Mo F, Huang Y, Zhao W, Fang P, Chen X, Teng X, Xu N, Lu Y, Yu X, Li Z, Zhang J, Wang H, Bao X, Zhou D, Chi Y, Zhou T, Zhou Z, Chen S, Teng L. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics. Gastric Cancer 2021. [PMID: 34095982 DOI: 10.1007/s10120-021-01201-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Farci P, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. Viruses 2021;13:830. [PMID: 34064419 DOI: 10.3390/v13050830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
18 Péneau C, Zucman-Rossi J, Nault JC. Genomics of Viral Hepatitis-Associated Liver Tumors. J Clin Med 2021;10:1827. [PMID: 33922394 DOI: 10.3390/jcm10091827] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé F, Teufel A. Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells 2021;10:648. [PMID: 33804045 DOI: 10.3390/cells10030648] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
20 Cerapio JP, Marchio A, Cano L, López I, Fournié JJ, Régnault B, Casavilca-Zambrano S, Ruiz E, Dejean A, Bertani S, Pineau P. Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry. Oncotarget 2021;12:475-92. [PMID: 33747361 DOI: 10.18632/oncotarget.27890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
21 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]